Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS)

Haematologica

Volumn 96, Issue 10, 2011, Pages 1433-1440

  Malcovati, Luca ^a   Porta, Matteo G Della ^a   Strupp, Corinna ^b   Ambaglio, Ilaria ^a   Kuendgen, Andrea ^b   Nachtkamp, Kathrin ^b   Travaglino, Erica ^a   Invernizzi, Rosangela ^a   Pascutto, Cristiana ^a   Lazzarino, Mario ^a   Germing, Ulrich ^b   Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anemia; Myelodysplastic syndromes; Outcome; WPSS

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GERMANY; HEART DEATH; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGNOSIS; SCORING SYSTEM; WHO CLASSIFICATION BASED PROGNOSTIC SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; FEMALE; HEART DISEASES; HUMANS; IRON OVERLOAD; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 80053186861     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.044602     Document Type: Article

References (38)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6): 536-8.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008.
3. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594-603.
4. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.
5. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-62.
6. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88.
7. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-10.
8. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351-1361.
9. Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):459-68.
10. Cazzola M. Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica. 2011;96(3):349-52.
11. Stone RM. How I treat patients with myelodysplastic syndromes. Blood. 2009; 113(25):6296-303.
12. Bowen DT, Fenaux P, Hellstrom-Lindberg E, de Witte T. Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. J Clin Oncol. 2008;26(7):1180; author reply 1-2.
13. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008;83(10):765-70.
14. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6(1):52-9.
15. Aul C, Gattermann N, Germing U, Runde V, Heyll A, Schneider W. Risk assessment in primary myelodysplastic syndromes: validation of the Dusseldorf score. Leukemia. 1994;8(11):1906-13.
16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-99.
17. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
18. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Bauman I, et al. Myelodysplastic syndromes/Neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008:88-93.
19. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
20. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19(6):716-23.
21. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26 (24):3913-5.
22. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441-9.
23. Riva E, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, et al. Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study. Haematologica. 2009;94(1):22-8.
24. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232-7.
25. Tang WH, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and longterm prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51(5):569-76.
26. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and metaanalysis. J Am Coll Cardiol. 2008;52(10): 818-27.
27. Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood. 1988;71(2):305-12.
28. Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leukemia research. 2009;33(12):1594-8.
29. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010; 116(9):2174-9.
30. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-52.
31. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCTCI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114-9.
32. Breccia M, Federico V, Latagliata R, Mercanti C, D'Elia GM, Cannella L, et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res. 2011;35(2):159-62.
33. Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26 (21):3607-13.
34. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574-82.
35. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for lowrisk myelodysplasia is associated with improved outcome. Blood. 2004;104(2): 579-85.
36. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13): 4606-13.
37. Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 2008;112(3):895-902.
38. Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, et al. Prognostic impact of pretransplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95(3):476-84.